W
arfarin is considered to be the standard-of-care therapy for many thromboembolic disorders.P In 2010, there were more than 32 million warfarin prescriptions in the US.3 Warfarin is frequently associated with unpredictable pharmacologic responses, ranging from occult bleeding to hemorrhage, due in part to its narrow therapeutic index.' Therefore, its action is closely monitored by means of frequent blood testing for the international normalized ratio (INR) determination, and dosage adjustments are often necessary. 2, 5, 6 The difference in successful outcomes during warfarin therapy is a multifactorial issue .?" Apart from the clinical and environmental variables, the individual's unique genetic make-up plays a fundamental role in the warfarin response.r'-' In January 2010, the Food and Drug Administration revised the warfarin label to include dosing recommendations based on genetic polymorphisms in genomewide association studies and identified CYP2C9 and vitamin K epoxide reductase subunit CI (VKORCI) as candidate Authorinformation provided at end of text.
acontributed equally to thiswork.
ble warfarindose is the steady-state dose that leads to stable anticoagulation levels, defined as 3 consecutive clinic visits for which INR measurements are within therapeutic range for the same meandaily dose," Finally, the therapeutic range was set at 2-3 or 2.5-3.5, according to indication for warfarin use. Patients were unrelated Hispanic Puerto Ricans whose parents were also born in Puerto Rico. The patients were receiving warfarin for diverse thromboembolicdisorders.
Demographic data such as age, sex, height, weight, and clinical nongenetic data (eg, stable warfarin daily dose, INR measurements from the beginning of warfarin therapy until patientstabilization, targetINR range,most recentactual INR value, primary indication for warfarin therapy, smoking status, concurrent medications, refill histories, concomitantdiseases) were obtained retrospectively from the computerized patientrecordsystem(CPRS).
LABORATORY ANALYSIS
Five milliliters of EDTA-treated bloodsamples were obtained from each patientat the time of routine INR testing. Genomic DNA sample was extracted and purified from whole fresh blood using QIAamp DNA Blood Midi Kit (QIAGEN Inc., Valencia, CA) following the manufacturer 's protocol. Extracted DNA was stored at -80·C in TRIS-EDTA (TE) buffer. Quantification of DNA was performed by fluorescent staining of double-stranded DNA (PicoGreen dsDNA Quantitation Kit, Molecular Probes, Eugene, OR). Fluorescentintensity was measured using a fluorescent micro-titer plate reader (BMG Labtech, FluoStar Optima,Germany).
Genotyping of the CYP2C9 and VKORCI genes at 12 variable sites,5 SNPs in CYP2C9 and 7 SNPs in VKORCI (Table 1) , was performed at Genomas(Clinical Laboratory 
STUDY COHORT
genes,"CYP2C9 encodesthe cytochrome P450, subfamily IIC, polypeptide 9, an enzyme responsible for metabolizing the more activeS-enantiomer of warfarin,":" Warfarin exerts its anticoagulant effect through inhibition of the VKORCI gene product. II, 30, 32 .34 Carriers of a common polymorphism in the VKORCI promoter sequence(-1639 G>A) may require a lowerwarfarin maintenance dosage. 3S,36 The -1639 G>A genotype and related haplotype can independently determine 20-25% of warfarin dose variance.P-" Together, the CYP2C9 and VKO-RC1 combinatorial genotypes account for up to 45% of warfarin dose variability.u, 22,24,30,3I,36 Nongenetic warfarin dosing algorithms may incorporate clinical factors such as body size and age but they rely on trial-and-error to achieve therapeutic dose, after an initial warfarin dose in the rangeof 2-10 mg.' Clinicians can now estimate the therapeutic dose a priori by genotyping their patients for single nucleotide polymorphisms (SNPs) that affect warfarin metabolism or sensitivity, theoretically reducingthe time neededto achieve targetdose and reducing the risk of adverse events.P-"
The primaryobjective of this retrospective study was to predict daily warfarin dosereduction in a Puerto Rican cohort of patients treated withwarfarin by using theircombinatorial CYP2C9 and VKORCI genotypes. Secondary objectives included an assessmentof the impactof CYP2C9 and VKO-RCI genotypes on time to dose stabilization and numberof out-of-range INRs. Finally, a comparison of dosepredictability between a published pharmacogenetic-guided model and both the clinical algorithm and fixed-dose approach was performed, usingcollected data from our study cohort.
bAglossary of genetic tenninology is maintained by the National Human Genome Research Institute at WWW.genome.gov/glossary. cfm.
Methods
A total of 106 warfarin-treated, stable patients from the Veterans Affairs Caribbean Healthcare System (VACHS)-affiliated anticoagulation clinic at San Juan, PuertoRico, were recruited, and they provided written consentas required by the institutional review board,Sta- 
STATISTICAL ANALYSIS
A cross-sectional analysis, retrospective association study was conducted.Allelic distribution frequencies were determined in this Puerto Ricanpopulation of warfarin-treated patients for the loci of interest. Departure from HardyWeinberg equilibrium (HWE) was estimated under the null hypothesis of the predictable segregation ratio of specific matching genotypes (p > 0.05) by use of X 2 goodness-of-fit testwith 1 degree of freedom. Statistical calculation indicated 80% powerto detectSNPs withallele frequencies of 0.1-0.4 in the study sample, accounting for 10%of phenotypic variationat lessthan5% of significance level.
To explore the study population-wide impact of polymorphisms on warfarin dose, we classified patients by . their combinatorial VKORCl and CYP2C9 genotypes. The expected reduction in dose for each combination was calculated by using a DNA-guidedequation publishedby the International Warfarin Pharmacogenetics Consortium (IWPC). 37 Effectivedaily warfarin dose was estimated for each combinatorial genotype, using the IWPC-derived equation," by substituting for average demographic characteristics of recruited patients. Mean (SD) predicted warfarin daily dose was computed for each combinatorial genotypeobservedin the study cohort as well as wild types (reference genotypes). The reductionin warfarin daily dose for each combinatorial genotypewas then calculated as the difference between the mean dose predicted for each particular combinatorial genotype and the mean dose predicted for the wild-type genotypes.
Using data from the studycohort,we alsocompared dose predictions from the IWPC-derived pharmacogenetic model with thosefrom 2 other models (ie, a clinical modelthat did not include genetic factors and the fixed dose of 5 mg/day of warfarin). The mean absoluteerror,defined as the mean of the absolutevalues for the difference betweenthe predicted and actualeffective dailywarfarin doses,and the coefficient of determination (R2) were used to evaluate each model's predictive accuracy: We evaluated the potential clinical value of each algorithm, following the sameapproach described by others," calculating the percentage of patients whosepredicted effective warfarin dose was within 20% of the actual effective dose.In addition, we calculated the percentage of patients for whom the predicteddose according-to each algorithm was at least 20% higher than the actual dose (overestimation) or at least 20% lower than the actual dose (underestimation). These values representa difference of 1 mg/day relative to the traditional starting dose of 5 mg daily, a difference that clinicians usuallyaccept as clinically relevant. Wealsoassessed theperformance of the algorithms in 3 dose groups: participants requiring a low dose (:5:3 mg/day), thoserequiring a highdose (~7 mg/day), and thoserequiring intermediate doses (>3 and <7 mg/day) for effective anticoagulation. Patients requiring doses of less than 3 mg/day would be at risk for excessiveanticoagulation if they were started on the standard doseof 5 mg/day. Conversely, patients requiring doses of more than 7 mg/day would be at risk for inadequate anticoagulation if treatmentwere started with 5 mg/day. The McNemartest of paired proportions was used for comparisonof the pharmacogenetic algorithmwith the clinical algorithm and the fixed-dose approach.
Nonparametric 2-tailed, unpaired Mann-Whitney U Wilcoxon rank-sum test for warfarin dose, time-to-target INR, age, height, and weight and Fisher exact test for comedications, smoking status, and primary indications were used to compare genotype groups (p < 0.05). Odds ratios (OR, 95% CI) adjustedby warfarin dose (milligrams per day) were estimated to show association between the CYP2C9 and VKORCl genotypesand the estimatesof the out-of-range INR ratio above 0.5 in Puerto Rican patients treated with warfarin at VACHS-San Juan, Puerto Rico. The out-of-rangeINR ratio is equal to the sum of the number of INRs above range plus the number of INRs below range divided by the total INR determinations during the initiation of therapy (ie, from initiation of warfarintherapy until achievement of therapeutic dose). An out-of-range INR ratio of 0.5 means that 50% of INR determinations are out-of-range during the initiation of therapy. Range is the INR therapeutic range as definedabove.
Our ability to detect a l-mg/day difference in dose due to genotypes,assuminga standarddeviation of 2.2 mg/day, required a minimum of 30 subjects per group (ie, carriers vs noncarriers) at 5% of significance and 80% power.
Results
Mean age of the participants was 65 years (range, , and 99% were men. Three patients were excluded from furtheranalyses becauseof poor genotyping call rate, which left the sample size at 103.In addition, 6 individuals were excludedfrom some assessments because of the lack of completeclinicaldata from CPRS (N =97). Table 2 summarizes patient characteristics by presence of I or more CYP2C9 and VKORCl variant alIeles (carriers) and wild-type (noncarrier) status. Notably, no significant differences between carriers and noncarriers withregard to clinical nongenetic and demographic variables were found,except for the daily warfarindose (p < 0.001). Consequently,
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WARFARIN DOSING PERGENOTYPE phisms. Table 3 presents the alleles, genotypes, and haplotype frequencies for the CYP2C9 and VKORCI markers. The frequency of the CYP2C9*2, *3, and *5 alleles was 19.1 %; 5.4%, and 1%, respectively. The VKORCl-1639A promoter allele was detected with a 41% frequency. The carrier prevalence calculated in this study sample , combining polymorph isms in both genes , was 68.9%, whereas noncarriers accounted for 31.1% of the study population . The percentage of subjects with polymorphisms in only a singlegene was 41.7%. Thirty-two patients were identified with a single polymorphism in CYP2C9 (*1/*2, *1/*3, or *1/*5),and 54 presented the VKORCl-1639 GA haplotype. Double carrier patients with either a singlepolymorphismin both CYP2C9 and VKORCI genes or with 2 allelic variantsin I of them accounted for 21.4% of the study population. Among them were 9 patients who carried a single CYP2C9 and single VKORCl polymorphism (eight *1*2/GA, one *1*3/GA) . Triple-carrier patients with a single polymorphism in CYP2C9 and double in VKORCl (one *1*2/AA), or double polymorphism in CYP2C9 and single in VKO-RCI (one *2*2/GA, three *2*3/GA), accounted for 4.9%. Only 1 quadruple carrier with double polymorphisms in both genes was detected (ie, *2*2/AA, -1%, n =103). No significant departure from HWE was found in this study (Xl <3.84, Table 3 ). Notably, the observed frequencies of least common VKORCl -1639 AA and CYP2C9 allelic variants in our study population were higher than expected (15 vs 10 and 10 vs 4.27, respectively) for perfect HWE, under a model of ascertainmentof 1 group.
Median actual effective doses of warfarin were compared by genotypes in a subset of 97 patients with complete clinical and genotyping data. Patients were grouped according to CYP2C9 and VKORCl carrier status as wildtypes or noncarriers, single, double, triple, and quadruple carriers. Significantdifferences were observed between carriers and noncarriers (p < 0.001, Table2) and acrosscarriergroups ( Figure  1) , with a clear decline in the median warfarin dose by increasing number of nonfunctional alleles (wild-type group 5.71 mg/day, singlecarriers 4.64 mg/daily,double carriers 3.43 mg/day, and 2.36 mg/day and 1.86 mg/dayfor tripleand quadruple carriers, respectively). 
The CYP2C9 genotypes were grouped as wildtype, 1 and 2 variant alleles according to the number of variant alleles (*2, *3, and *5) present. Average effective warfarin dose was stratifiedbased on CYP2C9 and VKORCl carrier status. Two distinct trends emerged. First , among Puerto Rican patients with a given CYP2C9 genotype, the daily warfarindose requirementsdeclined from the GG to the GA and AA genotypes. Second, within each VKORCl -1639 G>A genotype, the warfarin dose decreased as the number of variant CYP2C9 alleles increased. There was substantial overlap in the warfarin dose requirement across the combined genotype groups. Statistical analysis predicted that the effective warfarin daily dose in our population is dependent on genotypes.
No significant difference for the time to target INR between both groups was found ( Figure 2 depicts the projected effect of CYP2C9 and VKORCl combinatorial genotypes on warfarin dose reduction, using an early published DNA- 
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0.00~--r----,r---~---r--"'T""--~----,r---...,r--...,. The performanceof the pharmacogenetic,clinical, and fixed-dose models in the study cohort is shownin Tables 4 and5. In the low-dose subgroup (ie,highly sensitive patients at risk of serious bleeding episodes due to excessive anticoagulation), the pharmacogenetic algorithm provided dose estimates that weremoreaccurate and thussignificantly closerto the actual dosesrequired than theestimates derived from the clinical algorithm or the fixed-dose approach, as evidenced by a meanabsolute errorthatwas lowerthanthatfor boththe clinical algorithm and the fixed-dose approach (0.57 mg/day; 95% CI 0.37 to 0.77 vs 1.79 mg/day; 95% CI 1.45 to 2.13 and 3.51 rug/day: 95% CI 3.27 to 3.75, respectively; p < For patients whose warfarin dose requirement was 3 mg/day or less (-20% of the totalcohort),the pharmacogeneticalgorithm provided a significantly betterprediction of dose than did the clinical algorithm or the fixed-dose approach; 53% of the dose predictions fell within 20% of the actual (ie, ideal)dose with the pharmacogenetic algorithm compared with 6% with the clinical algorithm(p < 0.001) and 0% with the fixed-dose approach(p < 0.001). In addition, the pharmacogenetic algorithm provided significantly fewer overestimations of dose in the low-dose group (12% vs 94% with the clinical algorithm; p < 0.001, and 100% with the fixed-dose approach; p < 0.001) ( Table 5) . However,for patients requiring 7 mg or more per day (-12% of the total cohort),both the pharmacogenetic and the clinical algorithms underestimated the actualeffective dose of warfarin in our study cohort (both 100%). In the intermediatedose group,the accuracy of the dose prediction was similar betweenthe fixed-dose approach and the pharmacogenetic algorithm but poorerfor the latter with respectto the clinical approach. The analysis highlights the fact that this IPWC-derived pharmacogenetic algorithmprovided consistentlybetter dose predictionin an extreme subgroupof highly sensitive patients,but also suggeststhe need to improve predictability by developing a customized model for the PuertoRicanpopulation.
Overall, our study provides evidence on significantassociationsbetween genotypesand effective warfarin dosing in Puerto Rican patients, but not for the time to target INR or the numberof out-of-range INRs during the initial phase of warfarin therapy. The published pharmacogenetic algorithm yields stepwise dose reductions dependent on the numberof polymorphisms carriedby the patient.
Discussion
Findings in this study confirm the extensive interindividual variability of effective warfarin dose required to maintain the INR within the target range for prevention of different thromboembolic disorders. We evaluated the CYP2C9 and VKORCI gene SNPs in view of previous evidence that polymorphisms on these 2 genes are independent predictors of warfarin dose in multistep linear regression models. 8 ,l1 ,22,24,25,30,37 The study demonstrated a pharmacogenetic association between effective warfarin dose and combinatorial VKORCI and CYP2C9 genotypes. To our knowledge, this is the first time that such an association has been described in PuertoRican patients. bldeal dose was defined as a predicted dose within 20% of the actual stable therapeutic dose, underestimated dose was defined as a predicted dose at least 20% lower than the actual dose, and overestimated dose was defined as a predicted dose at least 20% higher than the actual dose.
There has beenuncertainty about frequencies of minoralleles expected in thePuerto Rican population because of a diverse mixture of Amerindian, European, and African ancestries. A fewreports haveincluded a limited number of Puerto Ricans as part of single Hispanicclusters,37,39.41 but ignore stratification and difference in SNP distributions within. We previously found that60% of subjects in a pilot study with 92 nontreated Puerto Ricanneonates werecarriers of polymorphismsin either CYP2C9 or VKORCI, predicting deficient warfarin metabolism or responsiveness," Notably, one samplecarried therareallele CYP2C9*6 (818delA, decreased activity) that is preferentially found in African descendants. This study extends those fmdings to a different population in a clinicalsetting. We found that 69% (-7 of 10)of patients werecarriers of at least 1 functional polymorphism in either of the2 warfarin-relevant genes.
The observed allele frequencies in this study (Table 3 ) were similarto thosereported in SNP databases suchas the International HapMapProject and studies analyzing populationsof mostly whiteancestry. The observed frequencies of common,functionally deficient CYP2C9*2, *3, and VKO-RCI-1639 G>A polymorphisms were 18.9% (resembling whites, 10-20%43.47),5.3% (resembling whites, 5_10%43.47), and 41% (resembling whites, 37.5-45%22, 24, 25, 35, 44, 45) , respectively. Current literature suggestssignificant differences in prevalenceof CYP2C9 and VKORCI polymorphisms between and within ethnic groupS. 25,35,43.49 Regarding VKORCI haplotypes, these ethnic differences contribute to lower warfarin doses in Asians and Mexicans,50,51 whereas African Americans have a high incidence of rare haplotypes. 25 '52 The uniqueness of the frequency distribution of VKORCI haplotypes in the Amerindians compared with otherpopulationshas beenpreviously discussed by Perini et al. 53 Whites havethe highest frequency of the *2 and *3 alleles, ranging from 10-20% and 5-10%,respectively. Africans havea very low *2 and *3 allele frequency, about 1% each. 17, 21, 22, 25, 31, 54 Accordingly, our study has contributed to filling a gap in existing knowledge of frequencies for CYP2C9 and VKORCI polymorphisrns in the admixed Puerto Rican population.
Basedon existing algorithms, Puerto Rican patients with I or 2 of these SNPs are expected to have reduced warfarin metabolism, lowerinitial doserequirements, a longer timeto dose stabilization, and a 2-to 3-foldelevated risk of an adverse eventwhenbeginning warfarin. 11, 21,23,30,52,55.57 According to ourfmdings,VKORCl-1639 G>A genotype proved to be the strongest predictor of effective warfarin dailydose,and thus needsto be considered in the further development of a PuertoRican customized,pharmacogenetic-driven, multivariatewarfarin dosingmodel.This conclusion may be extended to the CYP2C9 genotype-specific differences, because the effective warfarin daily dose requirement in our patient cohortdecreased significantly with the increase in the numberof variant CYP2C9 nonfunctional alleles (Figure 1) .
Predicting Warfarin DoseReductions in Puerto Ricans
Combinatorialgenotypes yield valuable information for potential DNA-guided adjustments in warfarin dosein Puerto Ricanpatients. Individuals withthe greatest numberof deficientpolymorphisrns willbenefit mostfromthisinformation (Figure 2 ). The predicted warfarin dose reduction ranged from 1.6mg/day to 4.9 mg/day for patients havingthe observed combinatorial genotypes. Thisfmding confirms thata pharmacogenetic approach can be recommended for reducing warfarin-induced adverse eventsin PuertoRicans. Currently, we are using a clinical protocol to develop a genomicbased warfarin dosing algorithm for thispopulation.
Data analysis results shown in Tables 4 and 5 suggest that the IWPC pharmacogenetic-guided algorithm provides betterpredictions of the optimal doseof warfarin thando either the clinical or a fixed-dose approach amongpatients in the study cohort whose stable therapeutic warfarin doses were3 mg or lessper day, but not among those whose stable doses were7 mg or moreperday. The former arepatients for whoman overdose couldhaveadverse clinical consequences such as life-threatening bleeds and intracranial hemorrhage. In this VACHS cohort, patients who require intermediate doses are likely to obtain little benefit fromuse of the IWPCderived pharmacogenetic algorithm. However, these results do not address the issueof whethera preciseinitialdose of warfarin translates into improved clinical endpoints, suchas reduced timeto achieve a stable therapeutic INR,feweroutof-range INRs,and reduced incidence of bleeding or thromboembolicevents. The IWPC pharmacogenetic algorithm performed lesspredictably among patients whorequired high doses of warfarin (>7 mg/day), because the common genetic markers included in the IWPC pharmacogenetic modelprimarily explain increased sensitivity to warfarin, notincreased resistance. Somepolymorphisms of VKORCI havebeen associated with resistanceto warfarin,but these variants are rarein the majority of populations and,therefore, not usually considered as independent predictors of dosevariability.
In general,publishedpharmacogenetic-guided warfarin dosing algorithms, such as the one developed by the IWPC, have performed poorly in predictingthe actual effective warfarindose among Puerto Rican patients,which explains the less than 36.3% of total variation in warfarin dose (absolute error of 7.9 mg/wk; 25% mean bias). This may be attributed to greater genetic diversity in the admixed Puerto Rican population and the possible influence of additional genes or other functional variants within the VKORCI and CYP2C910ci. A genomic-based algorithm can eventually improve model predictability in patients, particularly those who require high doses of warfarin.
To date, most of these algorithms are based on studies carried out in people of white ancestry. However,the rich genetic repertoire found in the Puerto Rican populationis likely to contribute substantially to variations in warfarin dose requirements, a component likelyto be missedby traditional studies in more homogeneous populations. This
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The Annals of Pharmacotherapy • 2012 February. Volume 46 • 215 addressable oversight is of great concern, since it will tend to exacerbate the health care disparity already experienced by Hispanic populations. Therefore, it is important to provide information on samples from other geographic regions, preferably from highly heterogeneous groups such as Puerto Ricans, to better understand the potential impact of such polymorphisms at the population level. Accordingly, our data have important implications in terms of the application of universally useful warfarin dosing algorithms, because differences in allele frequency distribution between groups of individuals of diverse ancestry can have an impact on the amount of variance in required warfarin dosing explained by the algorithms.
In addition to providing the first report to our knowledge on the frequency distribution of CYP2C9 and VKORCI polymorphisms in the heterogeneous warfarin-treated Puerto Rican patient population in Puerto Rico, our study has other significant strengths. First, we had access to complete information on all drugs being prescribed and dispensed, since the participants were provided with their medications at the study site. Such information could be relevant to identifying potential drug-warfarin interactions or for future clinical and epidemiologic studies in this pop-, ulation. Second, this study reflects real-life prescribing and dispensing of warfarin in the context of a health care facility in a LatinolHispanic territory. Third, the recruitment of warfarin-treated patients from a highly mixed population" provided evidence to support the notion that, in such populations, self-reported race/skin color categorization is not a reliable predictor of drug dosing (or drug choice) in the context of pharmacogenetic-informed clinical practice. We recognize that this study has some limitations, most of which have been described in previous studies with a similar design. First, given that our study was retrospective, the associations described must be prospectively tested in an appropriately large cohort. Second, although the clinical nongenetic covariates (eg, time to target INR, effective warfarin daily dose, comedications) were readily available in the patient's medical record, the genetic marker covariates, namely the CYP2C9 and VKORCI-1639 G>A genotypes, cannot be determined in a time frame compatible with the urgency of starting warfarin administration to many patients. Third, almost all patients enrolled in this study were elderly males from 1 medical facility; therefore, caution should be observed when trying to extrapolate our fmdings to other groups in this population. Finally, we did not address the impact of the covariates on the clinical response to warfarin, but instead used the INR as a surrogate for it. Still, limited sample size may preclude the estimation of statistically significant odds ratios, given the high interindividual variability in warfarin response at clinical settings.
Our work provides new evidence of significant prevalence of polymorphisms in warfarin-related genes within the Puerto Rican population and puts emphasis on the need to genotype high-risk warfarin-treated Puerto Rican patients before the induction phase of anticoagulation therapy. In so doing, we might be better able to understand dose variability in Puerto Rican patients so that anticoagulation therapy can be validated in the context of their unique genetic make-up.
This study lays important groundwork for supporting a prospective pharmacogenetic trial in the Puerto Rican population to detect the benefits of incorporating relevant genomic information into a customized DNA-guided warfarin dosing algorithm, particularly for patients who require low daily doses-the subgroup in this study for whom dose estimates based on the published pharmacogenetic algorithm differed significantly from those based on merely clinical, nongenetic variables.
